Anti-vascular endothelial growth factor (VEGF) agents—including aflibercept, bevacizumab, and ranibizumab—have ushered in a new era in the treatment of retinal and choroidal neovascularization.
This article was reviewed by Dr. Charles C. Wykoff, MD, PhD
New research has shown that a longer axial length (AL) may prove protective of incident diabetic retinopathy (DR).1
Genetic factors play a key role in the onset and progression of diabetic retinopathy, with 65 genes ifentified with several belonging to signaling pathways.
Tool is empowering patients to understand disease, become more involved in their treatment.
Visual cortical prosthesis intended to create artificial form of useful vision for blind individuals
ICYMI: Dr. Singh shares the take-home message from his 2019 presentation
ICMYI: Dr. Wykoff discusses results from his ASRS presentation
Sixty-five genes identified with several belonging to signaling pathways